England agrees funding for Gilead hepatitis C drug
April 17, 2014 at 11:43 AM EDT
LONDON, April 17 (Reuters) - Health authorities in England have approved an 18.7 million pound ($31 million) investment to provide Gilead Sciences' controversial new hepatitis C pill Sovaldi for seriously ill patients.